Načítá se...
Multiple Source Biosimilar Insulin, What’s a Provider to Do?
In the United States the FDA designates generic products that are bioequivalent as AB substitutable (FDA rating signifying the approved application contains adequate scientific evidence establishing through in vivo and/or in vitro studies the bioequivalence of the product to a selected reference pro...
Uloženo v:
| Vydáno v: | J Diabetes Sci Technol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4454116/ https://ncbi.nlm.nih.gov/pubmed/24876532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296813511748 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|